These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: IMMUNOGENETIC AND PHARMACOCHEMICAL CHARACTERIZATION OF THE ABO SYSTEM GLYCOPROTEIN PROPERTIES AS CRITERIA OF INDIVIDUAL SENSITIVITY TO ANTITUMOR AGENT BORTEZOMIB IN THE PLASMA CELL MYELOMA PATIENTS.
    Author: Minchenko ZM, Kustovska AD, Prymachenko SV, Dmytrenko OO, Liubarets TF, Shlyahtichenko TY, Balan VV, Bebeshko VG.
    Journal: Probl Radiac Med Radiobiol; 2019 Dec; 24():426-438. PubMed ID: 31841484.
    Abstract:
    OBJECTIVE: Experimental study of the effect profile of bortezomib in the plasma cell myeloma (PCM) patients depend- ing on a specific phenotype carrier state and a pharmacochemical characteristics of ABO system glycoproteins. MATERIALS AND METHODS: The research was conducted on the 104 PCM patients, including the Chornobyl NPP acci- dent survivors (n = 49) and 65 study subjects in the comparison group. Immunogenetic criteria for positive response to the applied treatment protocols were issued according to the duration of remission, absence of infectious com- plications, and evidence of chronic renal failure as a disease complication. RESULTS: Possibility of glycoproteins A and B participation in the formation of human biological individuality at a level of protein-protein interaction with antineoplastic drug bortezomib, which is widely used in cancer management prac- tice, in particular in the PCM treatment is considered. The glycoprotein B was shown being a selective target for borte- zomib, slowing down the recognition and interaction of antigen B with monoclonal anti-B antibody, while the agglu- tination period lengthens at that by 66 %. Assumption that the formation of bortezomib complex with glycoprotein B provides a background for interaction with the key reaction of proteasome 26S inhibition, which to some extent con- tributes to the drug effect retardation was confirmed through the quantum-chemical calculations. Equilibrium is shift- ed toward the main reaction leading to a higher drug efficacy in patients with blood groups O (I) and A (II). CONCLUSIONS: Since the complexation occurs predominantly in alkaline medium the administration of drugs with alkaline reaction should be restricted for at least round the clock after administration of bortezomib according to its half-life in plasma in patients with B (III) blood group and chronic renal failure. Meta roboty – eksperymental'ne doslidzhennia osoblyvostey̆ diï preparatu bortezomib u khvorykh na plazmokli- tynnu miielomu (PKM) zalezhno vid nosiy̆stva konkretnogo fenotypu i farmakokhimichnoï kharakterystyky glikopro- teïniv systemy AVO.Materialy i metody. Doslidzhennia provedeni u 104 khvorykh na PKM, sered nykh – 49 osib, postrazhdalykh vnaslidok avariï na ChAES, ta 65 patsiientiv grupy porivniannia. Imunogenetychni kryteriï pozytyvnoï vidpovidi na likuval'ni programy vyznachaly na osnovi tryvalosti remisiï, vidsutnosti infektsiy̆nykh uskladnen' i stupenia naiavnosti khronichnoï nyrkovoï nedostatnosti iak uskladnennia zakhvoriuvannia.Rezul'taty. Rozglianuta mozhlyvist' uchasti glikoproteïniv A i V u formuvanni biologichnoï indyvidual'nosti liudy- ny na rivni bilok-bilkovoï vzaiemodiï z likars'kym protypukhlynnym preparatom bortezomibom, iakyy̆ shyroko za- stosovuiet'sia v onkologichniy̆ praktytsi, zokrema pry likuvanni PKM. Dovedeno, shcho selektyvnoiu mishenniu dlia bor- tezomibu ie glikoproteïn V, shcho upovil'niuie rozpiznavannia i vzaiemodiiu antygena V z monoklonal'nym anty-V an- tytilom, pry ts'omu termin agliutynatsiï podovzhuiet'sia na 66 %. Kvantovo-khimichni rozrakhunky pidtverdyly prypu- shchennia, shcho reaktsiia utvorennia kompleksu bortezomibu z glikoproteïnom V skladaie pidgruntia formuvannia vzaie- modiï z osnovnoiu reaktsiieiu ingibuvannia proteasomy 26S, shcho, pevnoiu miroiu, spryiaie upovil'nenniu diï preparatu. Dlia patsiientiv z grupamy krovi O (I) i A (II) rivnovaga zmishchuiet'sia v bik osnovnoï reaktsiï, shcho zumovliuie vyshchu efek- tyvnist' preparatu.Vysnovky. Oskil'ky kompleksoutvorennia vidbuvaiet'sia perevazhno v luzhnomu seredovyshchi, patsiientam z grupoiu krovi V (III) ta naiavnoiu khronichnoiu nyrkovoiu nedostatnistiu rekomendovano obmezhuvaty vvedennia preparativ z luzhnoiu reaktsiieiu shchonay̆menshe protiagom doby pislia vvedennia bortezomibu, vidpovidno do periodu y̆ogo napiv- rozpadu v plazmi.
    [Abstract] [Full Text] [Related] [New Search]